Dianthus surges after mid-stage trial win for muscle-weakening drug

Dianthus Therapeutics

08/09/2025 16:36

Updates

** Shares of drug developer Dianthus Therapeutics DNTH.O rise 19.2% to a ten-month high of $31.6

** DNTH's experimental drug claseprubart improved symptoms in adults with generalized myasthenia gravis in a mid-stage trial, company says

** The 13-week trial enrolled 65 patients; they received shots under the skin every two weeks at either 300 mg, 600 mg, or a placebo

** Both doses of the drug led to statistically significant improvements in daily function and muscle strength, starting as early as the first week and sustained through week 13

** Dianthus plans to meet U.S. regulators after this Phase 2 study and aims to start a late-stage trial in 2026

** "We think claseprubart has even greater potential to shine clinically" Oppenheimer analysts say

** As of last close, DNTH stock up 21.6% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))